J&J's Velcade wins EU nod as induction therapy for multiple myeloma

08/12/2013 | PharmaTimes (U.K.)

The European Commission approved Johnson & Johnson's Velcade, or bortezomib, in combination with dexamethasone and thalidomide, as induction treatment for treatment-naive multiple myeloma patients who are candidates for stem cell transplant and high-dose chemotherapy. The approval strengthens Velcade's position in the multiple myeloma market.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT